Association of Varying Number of Doses of Quadrivalent Human Papillomavirus Vaccine With Incidence of Condyloma | Zendy

Eva Herweijer | Zendy; Amy Levál | Zendy; Alexander Ploner | Zendy; Sandra Eloranta | Zendy; Julia F. Simard | Zendy; Joakim Dillner | Zendy; Eva Netterlid | Zendy; Pär Sparén | Zendy; Lisen ArnheimDahlström | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Association of Varying Number of Doses of Quadrivalent Human Papillomavirus Vaccine With Incidence of Condyloma

Author(s) -

Eva Herweijer,

Amy Levál,

Alexander Ploner,

Sandra Eloranta,

Julia F. Simard,

Joakim Dillner,

Eva Netterlid,

Pär Sparén,

Lisen ArnheimDahlström

Publication year - 2014

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2014.95

Subject(s) - medicine , vaccination , poisson regression , incidence (geometry) , cervical cancer , population , cohort , hpv vaccines , hpv infection , demography , pediatrics , immunology , cancer , environmental health , physics , sociology , optics

Determining vaccine dose-level protection is essential to minimize program costs and increase mass vaccination program feasibility. Currently, a 3-dose vaccination schedule is recommended for both the quadrivalent and bivalent human papillomavirus (HPV) vaccines. Although the primary goal of HPV vaccination programs is to prevent cervical cancer, condyloma related to HPV types 6 and 11 is also prevented with the quadrivalent vaccine and represents the earliest measurable preventable disease outcome for the HPV vaccine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research